20 reports

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Biogen Inc Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 trials are taken as

  • Hormone
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine micro emulsion in cardiac transplant recipients.

  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NON CARDIAC DLTS WERE FATIGUE AND ABNORMAL LIVER FUNCTION TESTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Transplantation Proceedings; ##(##): ##-## Kees F, et al. (2007).

  • Dermatology
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

A third patient had a cardiac event (acute cardiac failure) during the first cycle and continued on CHOP alone.

  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative
  • Merck & Co., Inc.

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • Phase I - Trial Details

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICRO EMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NO LATE RENAL, LIVER, CARDIAC, OR OTHER TOXICITY WAS NOTED UP TO ## YEAR.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NOVARTIS PHARMACEUTICALS REGISTERED A ONE YEAR, MULTICENTER, OPEN-LABEL, SINGLE ARM, PILOT PHASE III STUDY OF THE RENAL SAFETY OF EVEROLIMUS IN ADDITION TO CYCLOSPORINE MICROEMULSION IN CARDIAC TRANSPLANT RECIPIENTS.

  • Hospital
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

NO LATE RENAL, LIVER, CARDIAC, OR OTHER TOXICITY WAS NOTED UP TO ## YEAR.

  • Endometrial Cancer
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Transplantation Proceedings; ##(##): ##-## Kees F, et al. (2007).

  • Dermatology
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

The primary outcome measure is to determine that any of the following complications after heart transplantation wound healing complications, pleural effusions (by chest X ray), pericardial effusions (by cardiac ultrasound), acute renal insufficiency by glomerular filtration

  • Targeted Therapy
  • Vaccine
  • United States
  • Product Initiative
  • Merck & Co., Inc.